25021-0416
                        
                    
                            Plerixafor
                        
                    
                                    Plerixafor
                                
                            
                        
                    
                            INJECTION, SOLUTION
                        
                    
                                    Subcutaneous
                                
                            
                        
                    
                                     PLERIXAFOR
                                
                                
                                     20.0
                                
                                
                                     mg/mL
                                
                                
                            
                        
                    
                                     25021-0416-01
                                
                                
                                     1 VIAL in 1 CARTON (25021-416-01)  / 1.2 mL in 1 VIAL
                                
                                
                                     Aug. 1, 2024
                                
                                
                                    Ancillary Therapy
                                
                            
                        
                    
                                    Immunostimulant
                                
                            
                        
                    
                                    Stem Cell Mobilizer
                                
                            
                        
                    
                            In Use
                        
                     An official website of the United States government
 An official website of the United States government
		 Home
 Home 
                             
                    